iGlarLixi versus basal plus Rapid‐Acting insulin in adults with type 2 diabetes advancing from basal insulin therapy: The SoliSimplify Real‐World study
Main finding · HbA1c change from baselineResult — go to the resultMean difference 0.1 % 95% one-sided CI −0.1 to 0.2Authors' conclusion
In real-world clinical practice, glycaemic outcomes 6 months after treatment advancement from BI are similar for people with T2D using iGlarLixi versus BI + RAI, with iGlarLixi leading to less weight gain.
Study context
- Population
- US adults ≥18 years with T2D on basal insulin advancing therapy, with ≥1 valid HbA1c value at baseline and at 6-month follow-up; Observational Medical Outcomes Partnership (OMOP) electronic medical recordsmatched cohort
- Participants
- 814 vs 814
- Exposure
- iGlarLixi vs basal insulin (BI) + rapid acting insulin (RAI)
- iGlarLixin = 814
- BI + RAIn = 814reference
- Outcome
- Non-inferiority of iGlarLixi to BI + RAI in HbA1c change from baseline (margin 0.3%)
- Follow-up
- 6 months
Methodological detailspropensity score matched, real-world, non-inferiority
- Propensity score matched
- Real-world
- Non-inferiority
Main finding
HbA1c change from baseline
Mean difference
0.1 %
95% one-sided CI −0.1 to 0.2
one-sided p = .0032
iGlarLixivs BI + RAI
mean difference 0.1 % (95% one-sided CI −0.1 to 0.2); one-sided p = .0032
As reported in the abstract
Observational data: associations, not effects.
Further findings
| Outcome | OR (95% CI) | P value | |
|---|---|---|---|
| HbA1c <7% without hypoglycaemia and weight gain | 1.15 (0.81–1.63) | P = 0.4280 | |
| 0.512Odds ratio (log scale) |
| Outcome | Estimate | P value |
|---|---|---|
| Weight gain · 6 monthsLower with iGlarLixi | −0.8 kg (CI −1.3 to −0.2) | two-sided p = .0069 |
HbA1c <7% without hypoglycaemia and weight gain
- Similar between groups
Safety
- Hypoglycaemia was low in both groups, probably because of underreporting
Original publication
iGlarLixi versus basal plus Rapid‐Acting insulin in adults with type 2 diabetes advancing from basal insulin therapy: The SoliSimplify Real‐World study. Diabetes Obes Metab. Published 19 September 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →